CytoSorbents vs Utah Medical Products
Utah Medical Products reported revenue of $38 million in fiscal 2025, about the same as CytoSorbents' $37 million in fiscal 2025. CytoSorbents' revenue grew 4.1% in its latest year, and Utah Medical Products' fell 5.8%. CytoSorbents had an operating margin of -39.8%, against 29.6% at Utah Medical Products. Free cash flow was −$13 million at CytoSorbents and $14 million at Utah Medical Products.
Side by side
| CytoSorbents | Utah Medical Products | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $37M | $38M |
| Revenue growth | 4.1% | −5.8% |
| Revenue growth a year, last 5 years | −2.0% | −1.8% |
| Gross margin | 71.5% | 57.1% |
| Operating margin | −39.8% | 29.6% |
| Net margin | −22.1% | 29.3% |
| Free cash flow | −$13M | $14M |
| Free cash flow margin | −33.8% | 37.2% |
| Return on capital | — | 26.8% |
| Net debt to EBITDA | — | −6.0x |
| Dividends and buybacks | $0M | $12M |
| Change in diluted share count | 14.3% | −7.5% |
| Last close | $5.13 | $70.96 |
| P/E at the last close | — | 21.2× |
| Insider trades, last 12 months | bought $269,332, sold $0 | — |
| Piotroski F-score | — | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CytoSorbentsUtah Medical Products
Operating margin
Percent of revenue
CytoSorbentsUtah Medical Products
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CytoSorbentsUtah Medical Products
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CytoSorbents and Utah Medical Products pages.